|
1
|
International agency for research on
cancer, GLOBOCAN 2012: Estimated cancer incidence, mortality and
prevalence. http://gco.iarc.fr/Worldwidein 2012.
|
|
2
|
Gupta S, Kumar P and Das BC: HPV:
Molecular pathways and targets. Curr Probl Cancer. 42:161–174.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hou MM, Liu X, Wheler J, Naing A, Hong D,
Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, et al: Targeted
PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A
phase I clinical experience. Oncotarget. 5:11168–11179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bregar AJ and Growdon WB: Emerging
strategies for targeting PI3K in gynecologic cancer. Gynecol Oncol.
140:333–344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tinker AV, Ellard S, Welch S, Moens F,
Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA and MacKay H: Phase
II study of temsirolimus (CCI-779) in women with recurrent,
unresectable, locally advanced or metastatic carcinoma of the
cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND
199). Gynecol Oncol. 130:269–274. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rashmi R, DeSelm C, Helms C, Bowcock A,
Rogers BE, Rader JL, Grigsby PW and Schwarz JK: AKT inhibitors
promote cell death in cervical cancer through disruption of mTOR
signaling and glucose uptake. PLoS One. 9:e929482014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genetics. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Granados López AJ and López JA: Multistep
model of cervical cancer: Participation of miRNAs and coding genes.
Int J Mol Sci. 15:15700–15733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma D, Zhang YY, Guo YL, Li ZJ and Geng L:
Profiling of microRNA-mRNA reveals roles of microRNAs in cervical
cancer. Chin Med J (Engl). 125:4270–4276. 2012.PubMed/NCBI
|
|
10
|
Cheung TH, Man KN, Yu MY, Yim SF, Siu NS,
Lo KW, Doran G, Wong RR, Wang VW, Smith DI, et al: Dysregulated
microRNAs in the pathogenesis and progression of cervical neoplasm.
Cell Cycle. 11:2876–2884. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu D, Liu C, Wang X, Ingvarsson S and
Chen H: MicroRNA-451 suppresses tumor cell growth by
down-regulating IL6R gene expression. Cancer Epidemiol. 38:85–92.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding H, Wu YL, Wang YX and Zhu FF:
Characterization of the microRNA expression profile of cervical
squamous cell carcinoma metastases. Asian Pac J Cancer Prev.
15:1675–1679. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Q, Tong S, Yan J, Hong C, Zhai W and Li
Y: Preparative separation of quaternary ammonium alkaloids from
Corydalis yanhusuo W. T. Wang by pH-zone-refining counter-current
chromatography. J Sep Sci. 34:278–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Y, Song KL, Chang H and Chen L:
Decreased expression of microRNA-126 is associated with poor
prognosis in patients with cervical cancer. Diagn Pathol.
9:2202014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang TH and Chu TY: Repression of miR-126
and upregulation of adrenomedullin in the stromal endothelium by
cancer-stromal cross talks confers angiogenesis of cervical cancer.
Oncogene. 33:3636–3647. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu R, Zhang YS, Zhang S, Cheng ZM, Yu JL,
Zhou S and Song J: MiR-126-3p suppresses the growth, migration and
invasion of NSCLC via targeting CCR1. Eur Rev Med Pharmacol Sci.
23:679–689. 2019.PubMed/NCBI
|
|
17
|
Luo W, Yan D, Song Z, Zhu X, Liu X, Li X
and Zhao S: miR-126-3p sensitizes glioblastoma cells to
temozolomide by inactivating Wnt/β-catenin signaling via targeting
SOX2. Life Sci. 226:98–106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujii T, Shimada K, Tatsumi Y, Fujimoto K
and Konishi N: Syndecan-1 responsive microRNA-126 and 149 regulate
cell proliferation in prostate cancer. Biochem Biophys Res Commun.
456:183–189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Otsubo T, Akiyama Y, Hashimoto Y, Shimada
S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and
contributes to gastric carcinogenesis. PLoS One. 6:e166172011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu Q, Liu SL, Wang H, Shi G, Yang P and
Chen XL: miR-126 suppresses the proliferation of cervical cancer
cells and alters cell sensitivity to the chemotherapeutic drug
bleomycin. Asian Pac J Cancer Prev. 14:6569–6572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawai S, Fujii T, Kukimoto I, Yamada H,
Yamamoto N, Kuroda M, Otani S, Ichikawa R, Nishio E, Torii Y, et
al: Identification of miRNAs in cervical mucus as a novel
diagnostic marker for cervical neoplasia. Sci Rep. 8:70702018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie
H, Zhou L, Wu J and Zheng S: MiR-126-3p suppresses tumor metastasis
and angiogenesis of hepatocellular carcinoma by targeting LRP6 and
PIK3R2. J Transl Med. 12:2592014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo C, Sah JF, Beard L, Willson JK,
Markowitz SD and Guda K: The noncoding RNA, miR-126, suppresses the
growth of neoplastic cells by targeting phosphatidylinositol
3-kinase signaling and is frequently lost in colon cancers. Genes
Chromosomes Cancer. 47:939–946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao J, Lin HY, Zhu YY, Zhu YP and Chen
LW: MiR-126 regulates proliferation and invasion in the bladder
cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt
signaling pathway. Onco Targets Ther. 9:5181–5193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu LY, Wang W, Zhao LY, Guo B, Yang J,
Zhao XG, Hou N, Ni L, Wang AY, Song TS, et al: Mir-126 inhibits
growth of SGC-7901 cells by synergistically targeting the oncogenes
PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol.
45:1257–1265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qu Y, Wu J, Deng JX, Zhang YP, Liang WY,
Jiang ZL, Yu QH and Li J: MicroRNA-126 affects rheumatoid arthritis
synovial fibroblast proliferation and apoptosis by targeting PIK3R2
and regulating PI3K-AKT signal pathway. Oncotarget. 7:74217–74226.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meng Q, Wang W, Yu X, Li W, Kong L, Qian
A, Li C and Li X: Upregulation of MicroRNA-126 contributes to
endothelial progenitor cell function in deep vein thrombosis via
its target PIK3R2. J Cell Biochem. 116:1613–1623. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vlachos IS, Paraskevopoulou MD, Karagkouni
D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL,
Maniou S, Karathanou K, Kalfakakou D, et al: DIANA-TarBase v7.0:
Indexing more than half a million experimentally supported
miRNA:mRNA interactions. Nucleic Acids Res. 43((Database Issue)):
D153–D159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Temkin SM, Yamada SD and Fleming GF: A
phase I study of weekly temsirolimus and topotecan in the treatment
of advanced and/or recurrent gynecologic malignancies. Gynecol
Oncol. 117:473–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Faried LS, Faried A, Kanuma T, Aoki H,
Sano T, Nakazato T, Tamura T, Kuwano H and Minegishi T: Expression
of an activated mammalian target of rapamycin in adenocarcinoma of
the cervix: A potential biomarker and molecular target therapy. Mol
Carcinog. 47:446–457. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tomao F, Di Tucci C, Imperiale L, Boccia
SM, Marchetti C, Palaia I, Muzii L and Panici PB: Cervical cancer:
Are there potential new targets? An update on preclinical and
clinical results. Curr Drug Targets. 15:1107–1120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wright AA, Howitt BE, Myers AP, Dahlberg
SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle
N, Jones RT, et al: Oncogenic mutations in cervical cancer: Genomic
differences between adenocarcinomas and squamous cell carcinomas of
the cervix. Cancer. 119:3776–3783. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wilting SM and Steenbergen RDM: Molecular
events leading to HPV-induced high grade neoplasia. Papillomavirus
Res. 2:85–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Macville M, Schrock E, Padilla-Nash H,
Keck C, Ghadimi BM, Zimonjic D, Popescu N and Ried T: Comprehensive
and definitive molecular cytogenetic characterization of HeLa cells
by spectral karyotyping. Cancer Res. 59:141–150. 1999.PubMed/NCBI
|
|
36
|
Vazquez-Mena O, Medina-Martinez I,
Juárez-Torres E, Barrón V, Espinosa A, Villegas-Sepulveda N,
Gómez-Laguna L, Nieto-Martinez K, Orozco L, Roman-Basaure E, et al:
Amplified genes may be overexpressed, unchanged, or downregulated
in cervical cancer cell lines. PLoS One. 7:e326672012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gonzalez E and McGraw TE: The Akt kinases:
Isoform specificity in metabolism and cancer. Cell Cycle.
8:2502–2508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tavares MR, Pavan IC, Amaral CL,
Meneguello L, Luchessi AD and Simabuco FM: The S6K protein family
in health and disease. Life Sci. 131:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pearce LR, Alton GR, Richter DT, Kath JC,
Lingardo L, Chapman J, Hwang C and Alessi DR: Characterization of
PF-4708671, a novel and highly specific inhibitor of p70 ribosomal
S6 kinase (S6K1). Biochem J. 431:245–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McCubrey JA, Fitzgerald TL, Yang LV,
Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M,
Neri LM, Cocco L, et al: Roles of GSK-3 and microRNAs on epithelial
mesenchymal transition and cancer stem cells. Oncotarget.
8:14221–14250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Suprynowicz FA, Kamonjoh CM, Krawczyk E,
Agarwal S, Wellstein A, Agboke FA, Choudhury S, Liu X and Schlegel
R: Conditional cell reprogramming involves non-canonical β-catenin
activation and mTOR-mediated inactivation of Akt. PLoS One.
12:e01808972017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim MS, Kim JH, Bak Y, Park YS, Lee DH,
Kang JW, Shim JH, Jeong HS, Hong JT and Yoon DY: 2,4-bis
(p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via
modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa
human cervical cancer cells. Nutr Cancer. 64:1236–1244. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bahrami A, Hasanzadeh M, Hassanian SM,
ShahidSales S, Ghayour-Mobarhan M, Ferns GA and Avan A: The
potential value of the PI3K/Akt/mTOR signaling pathway for
assessing prognosis in cervical cancer and as a target for therapy.
J Cell Biochem. 118:4163–4169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee CM, Fuhrman CB, Planelles V, Peltier
MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL and
Zempolich KA: Phosphatidylinositol 3-kinase inhibition by LY294002
radiosensitizes human cervical cancer cell lines. Clin Cancer Res.
12:250–256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xie G, Wang Z, Chen Y, Zhang S, Feng L,
Meng F and Yu Z: Dual blocking of PI3K and mTOR signaling by
NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and
enhances therapeutic response. Cancer Lett. 388:12–20. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cho SY, Choi M, Ban HJ, Lee CH, Park S,
Kim H, Kim YS, Lee YS and Lee JY: Cervical small cell
neuroendocrine tumor mutation profiles via whole exome sequencing.
Oncotarget. 8:8095–8104. 2017.PubMed/NCBI
|
|
48
|
Gagliardi PA, di Blasio L and Primo L:
PDK1: A signaling hub for cell migration and tumor invasion.
Biochim Biophys Acta. 1856:178–188. 2015.PubMed/NCBI
|
|
49
|
Xu J, Wang H, Wang H, Chen Q, Zhang L,
Song C, Zhou Q and Hong Y: The inhibition of miR-126 in cell
migration and invasion of cervical cancer through regulating ZEB1.
Hereditas. 156:112019. View Article : Google Scholar : PubMed/NCBI
|
